TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19588499

Group type: EXPERIMENTAL
Intervention: PicoGreen assay
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: QRTPCR
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: PicoGreen assay at cut-off point of 2.5 microg/ml
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: PicoGreen assay at cut-off point of 5.0 microg/ml
Number of subjects: 176
Study: 18041414

Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine cream
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 120
Study: 16218910

Group type: EXPERIMENTAL
Intervention: Temporary clipping used in 22 patients (group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No temporary clipping used in 18 patients (group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group of 20 volunteers (group C) without neurologic or psychiatric disorders
Number of subjects: 40
Study: 12360164

Group type: EXPERIMENTAL
Intervention: 10 mg of atorvastatin every other day
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 10 mg of atorvastatin every day
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Mean dose of atorvastatin in alternate-day group
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Mean dose of atorvastatin in every-day group
Number of subjects: 35
Study: 10428529

Group type: EXPERIMENTAL
Intervention: Oestradiol valerate 2 mg daily for six months
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 7482063

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 190

Group type: COMPARATOR
Intervention: Salazosulfapyridine
Number of subjects: 190
Study: 2184514

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 7233907

Group type: EXPERIMENTAL
Intervention: Ear-acupuncture
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo-acupuncture
Number of subjects: 13
Study: 30934166

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ertugliflozin (5 mg and 15 mg)
Number of subjects: 16
Study: 29779795

Group type: EXPERIMENTAL
Intervention: Yoga Nidra recording
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Relaxation music
Number of subjects: 144

Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 144
Study: 29548302

Group type: EXPERIMENTAL
Intervention: Dedicated approach (community health worker solely responsible for delivering mental health care)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Designated approach (community health worker provides mental health care in addition to usual responsibilities)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 1200
Study: 27295489

Group type: EXPERIMENTAL
Intervention: 100 mg immediate-release tapentadol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24880956

Group type: EXPERIMENTAL
Intervention: EAS prompting with 4% CHG (Group A1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: EAS prompting with 4% CHG (Group B1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-EAS (Group A2)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-EAS (Group B2)
Number of subjects: 80
Study: 22098077

Group type: EXPERIMENTAL
Intervention: Kidney transplant recipients (group 1)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Patients with chronic kidney disease (group 2)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Healthy controls (group 3)
Number of subjects: 110
Study: 19394731

Group type: EXPERIMENTAL
Intervention: 46.7% sodium citrate
Number of subjects: 232

Group type: COMPARATOR
Intervention: 5% heparin
Number of subjects: 232
Study: 17615904

Group type: EXPERIMENTAL
Intervention: Zinc gluconate (10 mg elemental zinc) added to multi-vitamin syrup containing vitamin A
Number of subjects: 200

Group type: COMPARATOR
Intervention: Multi-vitamin syrup containing vitamin A (control group)
Number of subjects: 200
Study: 18771134

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 77
Study: 11992160

Group type: EXPERIMENTAL
Intervention: Tetravalent rhesus‐human rotavirus vaccine (3 doses at 1st, 3rd, and 5th months of life)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Tetravalent rhesus‐human rotavirus vaccine
Number of subjects: 93
Study: 10379269

Group type: EXPERIMENTAL
Intervention: Titanium restorations
Number of subjects: 110

Group type: COMPARATOR
Intervention: Gold alloy restorations
Number of subjects: 110
Study: 8732146

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Filiform needle acupuncture (FNA)
Number of subjects: 40
Study: 2496428

Group type: EXPERIMENTAL
Intervention: 40 mg intravenous (IV) cocaine with 2.5 mg oral bromocriptine pretreatment
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 40 mg intravenous (IV) cocaine without bromocriptine pretreatment
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 1090892

Group type: EXPERIMENTAL
Intervention: Prednisone and vincristine therapy
Number of subjects: 37

Group type: COMPARATOR
Intervention: Vincristine alone
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Chronic prednisone therapy
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group of nephrotic syndrome patients not treated with prednisone
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Prednisone dosage
Number of subjects: 37
Study: 30936683

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Volume-matched normal saline (Group C)
Number of subjects: 90
Study: 28233020

Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 26296539

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once daily for 14 weeks
Number of subjects: 393

Group type: COMPARATOR
Intervention: Placebo once daily for 14 weeks
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg
Number of subjects: 393
Study: 22778174

Group type: EXPERIMENTAL
Intervention: Cinaciguat (100 μg/h starting dose, continuous i.v. infusion, titrated for 8 h and maintained for 16-40 h)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Cinaciguat
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study: 21740986

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 7
Study: 18633013

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tranexamic acid
Number of subjects: 50
Study: 17068190

Group type: EXPERIMENTAL
Intervention: 10-month Wa Do Ryu karate program
Number of subjects: 16

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 16
Study: 14506950

Group type: EXPERIMENTAL
Intervention: Vitamin K1 (1 mg/day) with mineral + vitamin D supplement (8 microg/day)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181

Group type: COMPARATOR
Intervention: Mineral + vitamin D supplement (MD group)
Number of subjects: 181
Study: 11320158

Group type: EXPERIMENTAL
Intervention: Donepezil augmentation
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 9988017

Group type: EXPERIMENTAL
Intervention: Derived ECGs
Number of subjects: 129

Group type: COMPARATOR
Intervention: Standard ECGs
Number of subjects: 129
Study: 7761959

Group type: EXPERIMENTAL
Intervention: Loderix (setastine)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Teldane (terfenadine)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Suprastin (chloropyramine HCl)
Number of subjects: 10
Study: 2904053

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg twice a day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Cholestyramine (8 g twice a day)
Number of subjects: 8
Study: 4847317

Group type: EXPERIMENTAL
Intervention: Jogging program (25 weeks, primarily jogging with some calisthenics)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Games program (equal time spent in swimming, volleyball, and bowling)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Jogging program
Number of subjects: 22

Group type: COMPARATOR
Intervention: Games program
Number of subjects: 22
Study: 31551368

Group type: EXPERIMENTAL
Intervention: IONIS‐APO(a)Rx (antisense oligonucleotide directed to apo(a))
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: IONIS‐APO(a)Rx
Number of subjects: 17
Study: 28606235

Group type: EXPERIMENTAL
Intervention: Sequential therapy combined with Lactobacillus
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Triple therapy combined with Lactobacillus
Number of subjects: 416

Group type: COMPARATOR
Intervention: Sequential therapy
Number of subjects: 416

Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Sequential-Lactobacillus group
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Triple-Lactobacillus group
Number of subjects: 416

Group type: COMPARATOR
Intervention: Sequential group
Number of subjects: 416

Group type: COMPARATOR
Intervention: Triple group
Number of subjects: 416
Study: 25606700

Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg subcutaneously every 2 weeks
Number of subjects: 103

Group type: COMPARATOR
Intervention: Ezetimibe 10 mg per os every day
Number of subjects: 103
Study: 23036567

Group type: EXPERIMENTAL
Intervention: PPV group (previous 23-gauge PPV and ILM peeling)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (senile cataract with healthy macula)
Number of subjects: 35
Study: 21317223

Group type: EXPERIMENTAL
Intervention: HPV+ patients
Number of subjects: 264

Group type: COMPARATOR
Intervention: HPV- patients
Number of subjects: 264
Study: 19736427

Group type: EXPERIMENTAL
Intervention: Patch and photopatch testing for allergic and photoallergic reactions to parthenium, xanthium, and chrysanthemum plant antigens
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 156
Study: 16364168

Group type: COMPARATOR
Intervention: Wheat allergen repertoire screening
Number of subjects: 21

Group type: COMPARATOR
Intervention: Maize allergen repertoire screening
Number of subjects: 21

Group type: COMPARATOR
Intervention: Evaluation of IgE-binding capacity of selected proteins
Number of subjects: 21
Study: 15042136

Group type: EXPERIMENTAL
Intervention: Grape-seed extract
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 11761026

Group type: EXPERIMENTAL
Intervention: Regular dose of omeprazole (20 mg once a day for 3 days, i.e. 60 mg/72 h)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: High dose of omeprazole (80 mg bolus + 8 mg/h for 3 days, i.e. 652 mg/72 h)
Number of subjects: 142
Study: 9259655

Group type: EXPERIMENTAL
Intervention: roxithromycin 150 mg orally twice a day
Number of subjects: 202

Group type: COMPARATOR
Intervention: placebo orally twice a day
Number of subjects: 202
Study: 30341268

Group type: EXPERIMENTAL
Intervention: Mouthwash with super-oxidized solution (SOS) Dermacyn® Wound Care
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.2% chlorhexidine gel (CHX)
Number of subjects: 20
Study: 27558002

Group type: EXPERIMENTAL
Intervention: NOAC group (dabigatran or rivaroxaban)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin group
Number of subjects: 0
Study: 24501143

Group type: EXPERIMENTAL
Intervention: Gain-framed messages
Number of subjects: 211

Group type: COMPARATOR
Intervention: Loss-framed messages
Number of subjects: 211
Study: 22942727

Group type: EXPERIMENTAL
Intervention: ASA + ER‐DP
Number of subjects: 425

Group type: COMPARATOR
Intervention: ASA monotherapy
Number of subjects: 425
Study: 18929360

Group type: EXPERIMENTAL
Intervention: 100 mg of oral micronized progesterone (OMP) twice a day
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 16883627

Group type: EXPERIMENTAL
Intervention: Chunghyul-dan (CHD) 600 mg three times a day for 8 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no medication, observation only)
Number of subjects: 35
Study: 15325864

Group type: EXPERIMENTAL
Intervention: Oral misoprostol 50 microg four hourly to maximum of 5 doses
Number of subjects: 70

Group type: COMPARATOR
Intervention: Continuous oxytocin infusion
Number of subjects: 70
Study: 11391688

Group type: EXPERIMENTAL
Intervention: Incremental net benefit expressed in units of cost
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cost minimization approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Incremental cost-effectiveness approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Incremental net benefit approach
Number of subjects: 0
Study: 9591893

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 97
Study: 7843390

Group type: EXPERIMENTAL
Intervention: Homoharringtonine (H.H)
Number of subjects: 47

Group type: COMPARATOR
Intervention: 5-Fluorouracil (5-FU)
Number of subjects: 47
Study: 2978461

Group type: EXPERIMENTAL
Intervention: Nebulization treatment with terbutaline and ipratropium bromide (given separately with a 30‐minute interval or combined as single inhalation)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Injection treatment with terbutaline (subcutaneously) and theophylline (intravenously)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Nebulization treatment with ipratropium bromide 30 minutes after terbutaline
Number of subjects: 77
Study: 31391011

Group type: EXPERIMENTAL
Intervention: Testosterone (100 mg weekly intramuscular injections for 7 weeks)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 27677733

Group type: EXPERIMENTAL
Intervention: VF biofeedback only
Number of subjects: 30

Group type: COMPARATOR
Intervention: ssEMG biofeedback only
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mixed biofeedback (VF for demonstration, ssEMG for training)
Number of subjects: 30
Study: 25287787

Group type: EXPERIMENTAL
Intervention: Higher baseline dispositional mindfulness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower baseline dispositional mindfulness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increases in waking cortisol
Number of subjects: 0
Study: 23247928

Group type: EXPERIMENTAL
Intervention: Isocaloric, protein-, and mineral-enriched postdischarge formula (PDF), n=52
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard term formula (TF), n=41
Number of subjects: 93

Group type: COMPARATOR
Intervention: Human milk (HM), n=46
Number of subjects: 93
Study: 21562190

Group type: EXPERIMENTAL
Intervention: Low-frequency MEG phase information during speech perception
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of frequency bands in classifier results
Number of subjects: 0
Study: 18852963

Group type: EXPERIMENTAL
Intervention: Direct and indirect intervention (TG)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Indirect intervention exclusively (OG)
Number of subjects: 11
Study: 17139244

Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with capecitabine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy with antiangiogenic agents
Number of subjects: 0
Study: 14978782

Group type: EXPERIMENTAL
Intervention: Active rTMS (10 sessions of 10-Hz rTMS to the left dorsolateral prefrontal cortex at 110% motor threshold)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 15
Study: 11252011

Group type: EXPERIMENTAL
Intervention: Experimental therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control therapy
Number of subjects: 0
Study: 9425767

Group type: EXPERIMENTAL
Intervention: Bio-Gide
Number of subjects: 25

Group type: COMPARATOR
Intervention: Gore-Tex
Number of subjects: 25
Study: 7684440

Group type: EXPERIMENTAL
Intervention: State definitions for at-risk children (composite)
Number of subjects: 985

Group type: EXPERIMENTAL
Intervention: Individual risk factors (e.g., hypothyroidism)
Number of subjects: 985

Group type: EXPERIMENTAL
Intervention: Commonly identified risk factors
Number of subjects: 985
Study: 3120486

Group type: EXPERIMENTAL
Intervention: alfentanil and thiopentone induction, 66% N2O maintenance
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: alfentanil and midazolam sedation prior to isoflurane and N2O induction and maintenance
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: midazolam and alfentanil induction; oxygen/air, placebo reversal
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: midazolam and alfentanil induction, oxygen/air, flumazenil reversal
Number of subjects: 100
Study: 31859211

Group type: EXPERIMENTAL
Intervention: One-stop myocardial computed tomography perfusion (CTP)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Conventional coronary CT angiography (CCTA)
Number of subjects: 442
Study: 31078564

Group type: EXPERIMENTAL
Intervention: Presentation + Mastery (n=58)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Presentation (n=61)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 119
Study: 28101567

Group type: EXPERIMENTAL
Intervention: Arm crank ergometer training
Number of subjects: 49

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 49
Study: 25287262

Group type: EXPERIMENTAL
Intervention: Semiautomatic volumetric software with a threshold of -300 HU
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Semiautomatic volumetric measurements at a threshold of -130 HU
Number of subjects: 115
Study: 24057294

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg/d (increased to 45 mg/d after 1 month)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 156
Study: 21765448

Group type: EXPERIMENTAL
Intervention: iptakalim (5 or 10 mg/d, po) for 8 weeks
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: TT genotype for A190A polymorphism
Number of subjects: 162
Study: 19807917

Group type: EXPERIMENTAL
Intervention: Standard treatment plus dalteparin (5000 IU daily subcutaneous injection for 24 weeks)
Number of subjects: 2200
Study: 16677149

Group type: EXPERIMENTAL
Intervention: IFN-alpha 2b plus lamivudine
Number of subjects: 26

Group type: COMPARATOR
Intervention: IFN-alpha 2b
Number of subjects: 26
Study: 14667697

Group type: EXPERIMENTAL
Intervention: Pronouns with infrequent antecedents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pronouns with frequent antecedents
Number of subjects: 0
Study: 11594714

Group type: EXPERIMENTAL
Intervention: Counseling service model for couples participating in ART
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine procedures currently included in ART (Control group)
Number of subjects: 60
Study: 11189315

Group type: EXPERIMENTAL
Intervention: Gu Chi Gao
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 24
Study: 7955998

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3150952

Group type: EXPERIMENTAL
Intervention: Cefotetan (2 g i.v. at induction, two additional doses every 12 h)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Clindamicin (600 mg i.v. at induction) plus Aztreonam (1 g i.v., two additional doses every 8 h)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Clindamicin plus Aztreonam
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 65
Study: 30616868

Group type: EXPERIMENTAL
Intervention: STN+SNr‐DBS
Number of subjects: 15

Group type: COMPARATOR
Intervention: STN‐DBS
Number of subjects: 15
Study: 28527156

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aerobic-strength exercise
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 25771714

Group type: EXPERIMENTAL
Intervention: Tumescent suction curettage (TSC)
Number of subjects: 30
Study: 24704090

Group type: EXPERIMENTAL
Intervention: Topical clobetasol propionate 0.05%
Number of subjects: 58

Group type: COMPARATOR
Intervention: Topical tacrolimus 0.1%
Number of subjects: 58
Study: 23000693

Group type: EXPERIMENTAL
Intervention: Standardised respiratory physiotherapy (positioning, thoracic vibration, thoracic compression, positive expiratory pressure, breathing exercises, forced exhalation with the glottis open or 'huffing') three times daily.
Number of subjects: 72

Group type: COMPARATOR
Intervention: Non-mandatory request to breathe deeply, expectorate sputum, and maintain a lateral body position once a day.
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (non-mandatory request)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Intervention group (chest physiotherapy)
Number of subjects: 72
Study: 19647670

Group type: EXPERIMENTAL
Intervention: Correction method based on waist girth applied to dual-energy X-ray absorptiometry output
Number of subjects: 0
Study: 17596730

Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation (PAV)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Patient-Triggered Ventilation (PTV)
Number of subjects: 22
Study: 15052871

Group type: EXPERIMENTAL
Intervention: Laser therapy
Number of subjects: 70
Study: 14612206

Group type: EXPERIMENTAL
Intervention: Vitamin C 2 g/day plus Vitamin E 400 IU/day (Group B)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Vitamin C 2 g/day plus Vitamin E 800 IU/day (Group C)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Vitamin C 2 g/day (Group A)
Number of subjects: 43

Group type: COMPARATOR
Intervention: No antioxidant treatment (Group D)
Number of subjects: 43
Study: 9768015

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7662437

Group type: EXPERIMENTAL
Intervention: Nursing diagnosis assessment by student and registered nurses
Number of subjects: 100
Study: 2502441

Group type: EXPERIMENTAL
Intervention: Short‐Buserelin‐gonadotropin regimen
Number of subjects: 262

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC)/hMG regimen
Number of subjects: 262
Study: 332191

Group type: EXPERIMENTAL
Intervention: Vincamine (60 mg p.o. daily for 6 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30